Vestnik otorinolaringologii 2011-01-01

[Cochleovestibular disorders: approaches to diagnostics and treatment].

O V Zaĭtseva

Index: Vestn. Otorinolaringol. (5) , 55-8, (2011)

Full Text: HTML

Abstract

The aim of this work was to evaluate the efficacy of introduction of milgamma and milgamma compositum in the treatment of 52 patients with cochleovestibular disorders of different etiology. Thirteen patients enrolled in the study received standard therapy and 39 others were given its combination with milgamma preparations. Combined therapy with milgamma and milgamma compositum ensured faster vestibular compensation including posturographic characteristics than the standard treatment (within 3-4 weeks compared with 5 weeks in controls). The results of the study give reason to recommend milgamma and milgamma compositum as neurotropic medicines in addition to standard therapy for the management of the patients presenting with cochleovestibular disorders for the acceleration of the vestibular compensation.


Related Compounds

Related Articles:

Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives.

2008-01-01

[BMC Pharmacol. 8 , 10, (2008)]

The detrimental effects of acute hyperglycemia on myocardial glucose uptake.

2014-06-06

[Life Sci. 105(1-2) , 31-42, (2014)]

The effect of benfotiamine on mu-opioid receptor mediated antinociception in experimental diabetes.

2014-03-01

[Exp. Clin. Endocrinol. Diabetes 122(3) , 173-8, (2014)]

Boosting the pentose phosphate pathway restores cardiac progenitor cell availability in diabetes.

2013-01-01

[Cardiovasc. Res. 97(1) , 55-65, (2013)]

Advanced glycation end-products inhibition improves endothelial dysfunction in rheumatoid arthritis.

2012-02-01

[Int. J. Rheum. Dis. 15(1) , 45-55, (2012)]

More Articles...